XC-130
Pharmaceutical compound
From Wikipedia, the free encyclopedia
XC-130, or XC130, also known as XC130-A10H, is a dopamine receptor agonist which is under development for the treatment of Parkinson's disease.[1][4][2][3] It is taken orally.[1][2][3]
| Clinical data | |
|---|---|
| Other names | XC130; XC130-A10H |
| Routes of administration | Oral[1][2][3] |
| Drug class | Dopamine receptor agonist; Antiparkinsonian agent |
The drug is a dopamine D2 receptor partial agonist, a dopamine D3 receptor antagonist, an α1A-adrenergic receptor antagonist, and a serotonin 5-HT1B, 5-HT2A, and 5-HT2B receptor antagonist.[2] Its potency as a dopamine D2 receptor agonist is similar to that of lisuride.[2] XC-130 produces antiparkinsonian-like effects in animals.[3] Due to its pharmacological profile, the drug is expected to avoid adverse effects and toxicity such as obsessive–compulsive symptoms (related to D3 agonism), vasoconstriction (related to α1A-adrenergic and 5-HT1B agonism), hallucinogenic effects (related to 5-HT2A agonism), and cardiac valvulopathy (related to 5-HT2B agonism).[2] It has a notably longer elimination half-life than the relatively short-acting lisuride.[2] The drug is intended to provide similar therapy as existing ergoline dopamine receptor agonists like pergolide and lisuride but with an improved drug profile.[2][3]
XC-130 is under development by Xoc Pharmaceuticals.[1][4] As of November 2022, it is in phase 1/2 clinical trials.[1][4] The chemical structure of XC-130 does not yet appear to have been disclosed.[1]